Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial by Parkes-Ratanshi, Rosalind et al.
  
 
 
 
 
 
 
 
 
Parkes-Ratanshi, Rosalind, Wakeham, Katie, Levin, Jonathan, Namusoke, 
Deodata, Whitworth, James, Coutinho, Alex, Mugisha, Nathan Kenya, 
Grosskurth, Heiner, Kamali, Anatoli, and Lalloo, David G. (2011) Primary 
prophylaxis of cryptococcal disease with fluconazole in HIV-positive 
Ugandan adults: a double-blind, randomised, placebo-controlled 
trial. Lancet Infectious Diseases, 11 (12). pp. 933-941. ISSN 1473-3099  
 
 
Copyright © 2014 The Authors 
  
  
http://eprints.gla.ac.uk/94775/ 
 
 
 
Deposited on:  27 June 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
www.thelancet.com/infection   Vol 11   December 2011 933
Articles
Lancet Infect Dis 2011; 
11: 933–41
Published Online
October 7, 2011 
DOI:10.1016/S1473-
3099(11)70245-6
See Comment page 892
Medical Research Council 
(MRC)/Uganda Virus Research 
Institute (UVRI) Uganda 
Research Unit on AIDS, UVRI, 
Entebbe, Uganda 
(R Parkes-Ratanshi PhD, 
K Wakeham MRCP, 
Prof J Levin PhD, 
Prof H Grosskurth PhD, 
A Kamali MSc); Liverpool School 
of Tropical Medicine, Liverpool, 
UK (R Parkes-Ratanshi, 
K Wakeham, 
Prof D G Lalloo FRCP); 
Department of Infectious 
Diseases, Imperial College of 
Science and Technology, 
London, UK (R Parkes-Ratanshi); 
University of Witwatersrand, 
Johannesburg, South Africa 
(Prof J Levin); The AIDS Support 
Organisation (TASO), Masaka, 
Uganda (D Namusoke MA, 
A Coutinho MPH); Wellcome 
Trust, London, UK 
(J Whitworth PhD); Infectious 
Diseases Institute, Kampala, 
Uganda (A Coutinho); Ministry 
of Health, Kampala, Uganda 
(N K Mugisha MPH); and 
London School of Hygiene and 
Tropical Medicine, London, UK 
(Prof H Grosskurth)
Correspondence to:
Dr Rosalind Parkes-Ratanshi, 
C/o MRC Unit on AIDS in Uganda, 
PO Box 49, Entebbe, Uganda
r.parkes@imperial.ac.uk
Primary prophylaxis of cryptococcal disease with ﬂ uconazole 
in HIV-positive Ugandan adults: a double-blind, randomised, 
placebo-controlled trial
Rosalind Parkes-Ratanshi, Katie Wakeham, Jonathan Levin, Deodata Namusoke, James Whitworth, Alex Coutinho, Nathan Kenya Mugisha, 
Heiner Grosskurth, Anatoli Kamali, David G Lalloo, on behalf of the Cryptococcal Trial Team
Summary
Background Cryptococcal disease remains an important cause of morbidity and mortality in HIV-infected individuals 
in sub-Saharan Africa, despite the intro duction of antiretroviral therapy. We studied ﬂ uconazole as primary prophylaxis 
against cryptococcal disease in patients awaiting or starting antiretroviral therapy in Uganda.
Methods In this prospective, double-blind randomised controlled trial, we enrolled HIV-positive adults with CD4 
counts less than 200 cells per μL, cryptococcal antigen (CrAg)-negative, naive for antiretroviral therapy, and coming 
from ﬁ ve local AIDS organisations in Masaka district, Uganda. Enrolment took place between Sept 14, 2004, and 
Feb 1, 2008. Participants were randomly allocated to placebo or 200 mg ﬂ uconazole three times per week (1:1) in 
blocks of 40. Randomisation was done with ralloc procedure in Stata. Participants were reviewed after 4 weeks and 
referred for antiretroviral therapy, then seen every 8 weeks. Participants discontinued trial treatment when CD4 
counts reached 200 cells per μL (median 197 days). Primary endpoints were invasive cryptococcal disease and all-
cause mortality. Secondary endpoints were time to ﬁ rst episode and incidence of oesophageal candidosis, time to ﬁ rst 
episode and incidence of oropharyngeal or vaginal candidosis, and time to ﬁ rst hospital admission or death. The 
primary safety endpoint was cessation of trial drug because of transaminase concentrations higher than ﬁ ve times the 
upper limit of normal (ULN), or other major adverse events. Analyses were done by intention to treat and included all 
participants enrolled in the trial. Participants and researchers were masked to group assignment. This trial is 
registered with controlled-trials.com, number ISRCTN 76481529.
Results Of 1519 individuals enrolled, 760 participants received ﬂ uconazole and 759 received placebo. 19 developed 
cryptococcal disease, one in the ﬂ uconazole group and 18 in the placebo group (p=0·0001); adjusted HR (aHR) 18·7 
(95% CI 2·5–140·7). One case of cryptococcal disease could be prevented by treating 44·6 patients with baseline CD4 
counts lower than 200 cells per μL. Fluconazole was eﬀ ective against cryptococcal disease both before (aHR=11·0 
[1·4–85·3]) and after start of antiretroviral therapy (no cases in ﬂ uconazole vs seven cases on placebo). Seven 
participants died from cryptococcal disease, none in the ﬂ uconazole group. All-cause mortality (n=189) did not diﬀ er 
between the two groups (p=0·46). Fluconazole reduced the time to ﬁ rst episode of oesophageal, and oropharyngeal 
and vaginal candidosis,  as well as the incidence of all candidosis (p<0·0001), but had no eﬀ ect on hospital admission 
or death. The frequency of elevated transaminases (>5×ULN) was similar between groups (aHR=0·94 [0·65–1·35]).
Conclusions Fluconazole was safe and eﬀ ective as primary prophylaxis against cryptococcal disease, both before and 
during early antiretroviral treatment. Cryptococcal infection was less common than anticipated because of the rapid 
commencement of antiretroviral therapy and exclusion of those with positive CrAg. In patients with negative CrAg on 
screening, ﬂ uconazole prophylaxis can prevent cryptococcal disease while waiting for and in the early weeks of 
antiretroviral therapy, particularly in those with CD4 counts of less than 100 cells per μL.
Funding Medical Research Council, UK, and Rockefeller Foundation.
Background
Cryptococcal disease is one of the most common CNS 
infections in individuals with HIV. Infection is acquired 
by inhalation of environmental spores or desiccated yeast 
cells: clinical disease might not occur for months to years 
after exposure and might be preceded by asymptomatic 
cryptococcal antigenaemia.1 The disease is particularly 
problematic in sub-Saharan Africa, where the incidence 
in severe immunosuppression can reach 10% yearly and 
it can cause up to 17% of deaths in individuals with HIV.1,2 
Untreated, the mortality is 100% for those with HIV and, 
even with optimum treatment, about 30% of individuals 
die.3,4 Survivors often have severe disabilities.5 The gold 
standard treatment of amphotericin and ﬂ ucytosine is 
costly and diﬃ  cult to administer in resource-poor 
settings,4,6 ﬂ uconazole is therefore often used with poorer 
outcomes.7,8
Before the availability of antiretroviral therapy in the 
USA, results from a randomised controlled trial of 
primary prophylaxis with ﬂ uconazole showed a reduction 
in the incidence of cryptococcal disease but no eﬀ ect on 
mortality.9 Other studies10–18 suggested beneﬁ t from 
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routine prophylaxis with itraconazole or ﬂ uconazole, but 
most were small and retrospective. A Cochrane review19 
of cryptococcal primary prophylaxis concluded that azoles 
reduced incidence of cryptococcal disease but that the 
eﬀ ect on mortality was unclear, and that studies were 
needed in the developing world.19 Only two studies have 
been done in developing countries,20,21 both in Thailand 
and with less than 10% of participants receiving 
antiretroviral therapy. Results from one of these studies20 
suggested that ﬂ uconazole prophylaxis reduced invasive 
fungal infections and mortality, but had no eﬀ ect on 
cryptococcal events; results from the other21 showed a 
reduction in systemic fungal diseases (including 
cryptococcosis) with itraconazole but no survival 
advantage.21
The incidence of cryptococcal disease has recently 
declined in industrialised countries, predominantly 
because of antiretroviral therapy.22–24 International 
initiatives led to progress in the provision of antiretroviral 
therapy in resource-poor countries, but only 30% of those 
who need this therapy in sub-Saharan Africa are receiving 
it.25 Cryptococcal disease remains common in sub-
Saharan Africa, both in those who are yet to start and 
those who are in the ﬁ rst months of antiretroviral 
therapy.26,27
Primary prophylaxis against cryptococcal disease has 
never been formally tested in Africa or any setting in 
which eﬀ ective antiretroviral therapy is available. We 
aimed to examine the eﬃ  cacy and safety of ﬂ uconazole 
as primary prophylaxis against cryptococcal disease 
before initiation and in the ﬁ rst few months of 
antiretroviral therapy.
Methods
Study design and participants
In this double-blind, randomised, placebo-controlled 
trial, we recruited participants between Sept 14, 2004, and 
Feb 1, 2008, from ﬁ ve local HIV/AIDS organisations in 
Masaka and Kalangala districts, Uganda: the AIDS 
Support Organisation (TASO), Masaka Regional Referral 
Hospital, Uganda Cares Masaka, Kalangala District 
Health Services, and Kitovu Mobile AIDS Organisation. 
Participants were from pre dominantly rural communities, 
including the Ssese islands in Lake Victoria.
We screened potential participants for eligibility at a 
dedicated study clinic sited at TASO; from April, 2006, 
we also screened and enrolled participants at Ministry of 
Health clinics on the Ssese islands. Adults naive for 
antiretroviral therapy with laboratory conﬁ rmation of 
HIV infection (Murex HIV-1.2.0, Murex Biotech, Dartford, 
UK; Vironostika HIV Uni-form II plus O, Biomerieux, 
Marcy l’Etoile, France; Cambridge Biotech HIV-1 Western 
blot, Maxim Biomedical In, Rockville, USA) and a CD4 
count of less than 200 cells per μL (FACSCount Becton 
Dickinson, USA) were eligible for the study. We tested 
for cryptococcal antigen (CrAg; Remel, Lexana, USA; 
dilution ﬁ rst done to exclude pronase eﬀ ect) and excluded 
participants with a serum titre of CrAg higher than 1/8; it 
was deemed unethical to randomise these patients. Other 
exclusion criteria were pregnancy or lactation, 
concentrations of liver trans aminases (liver-function test) 
more than three times the upper limit of normal (ULN), 
and moribund patients. Participants with oral and vaginal 
candidosis at screening were treated with topical 
clotrimazole or nystatin, or if refractory, ketoconazole 
(200–400 mg daily for 5 days); symptomatic oesophageal 
candidosis was treated with ﬂ uconazole (minimum 
14 days) and enrolment delayed for 4 weeks.
Information about the trial was provided during group 
and individual meetings and through leaﬂ ets in the local 
language. Participants gave written or, if illiterate, 
witnessed (by a person independent of the trial team) 
verbal consent to screening and enrolment. Ethics 
approval was gained from the Uganda National Council 
for Science and Technology and the Ethics Committees 
of Uganda Virus Research Institute (UVRI), Uganda, and 
the Liverpool School of Tropical Medicine, UK. An 
independent data monitoring committee monitored 
accumulating data regularly. At completion of the trial, 
all participants were oﬀ ered ﬂ uconazole if their CD4 
count was still below 200 cells per μL.
Randomisation and masking
An independent statistician prepared a list for random-
isation to ﬂ uconazole or matching placebo (1:1) in 
random permuted blocks of size 40. Randomisation was 
not stratiﬁ ed by site. Trial drug was packaged and labelled 
by an independent clinician and pharmacist. Participants 
were allocated to sequential trial numbers on enrolment 
and received the corresponding sealed trial drug pack 
from a trial nurse. Blinded samples of trial drug were 
assessed at the University of Liverpool, UK, for 
consistency with trial drug labelling. Participants, trial 
medical staﬀ , data management team, and endpoint 
committee were masked to group assignment.
Trial procedures
Eligible and consenting participants were enrolled and 
received either 200 mg of ﬂ uconazole or matching placebo 
(manufactured by Cipla, India) three times a week. 
Participants were seen 4 weeks after enrolment and then 
every 8 weeks for follow-up. New clinical symptoms or 
signs were assessed and inter current illnesses treated. 
Pill counts and adherence to trial medication were 
assessed at routine visits to encourage adherence. Liver-
function tests were done every 8 weeks and CD4 counts 
measured every 16 weeks. A serum sample was stored at 
every follow-up for subsequent CrAg testing. Women 
were tested for pregnancy, counselled about avoiding 
pregnancy, and oﬀ ered contraception at every 
appointment. Patients were oﬀ ered co-trimoxazole 
(trimethoprim–sulfameth oxazole) prophylaxis (480 mg 
daily) according to national guidelines. Participants were 
encouraged to attend the clinic or contact the trial team if 
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they felt unwell between routine visits and, if necessary, 
were admitted to hospital under the care of the trial team. 
Field workers attempted to contact non-attendees at home 
if a routine appointment was missed.
Suspected cryptococcal cases were investigated with a 
serum CrAg test, chest radiograph, blood cultures 
(BACTEC 9120 blood culture system, Becton Dickinson, 
Franklin Lakes, USA) and lumbar puncture (routine 
cerebrospinal ﬂ uid [CSF] microscopy, India ink 
microscopy, glucose analysis, and CSF culture at 37°C for 
14 days on Sabouraud dextrose agar). Invasive cryptococcal 
disease was deﬁ ned as symptoms of crypto coccal disease 
with a serum CrAg titre higher than 1/8 on two occasions, 
or a CSF positive for CrAg, or Cryptococcus neoformans 
grown from blood or CSF culture.
Participants who developed cryptococcal disease were 
treated with amphotericin (0·8–1·0 mg/kg daily, 
intravenously) for 14 days followed by ﬂ uconazole 400 mg 
daily for 8 weeks, and secondary ﬂ uconazole prophylaxis 
(200 mg daily). Oral and vaginal candidosis was diagnosed 
by culture and treated with topical nystatin or clotrimazole; 
refractory cases received oral ketoconazole (200–400 mg 
daily for 5 days). Oesophageal candidosis was diagnosed 
by dysphagia with a positive oropharyngeal culture, and 
treated with ﬂ uconazole 200 mg daily for 2 weeks; trial 
drug was suspended during this period.
The trial was designed before the availability of 
antiretroviral therapy in Uganda. In the ﬁ rst year of the 
trial, antiretroviral therapy free of charge became widely 
available and trial protocols were modiﬁ ed. At the initial 
4-week follow-up, patients’ liver function was tested to 
exclude side-eﬀ ects of trial drug, and participants were 
given a referral letter to their preferred care provider of 
antiretroviral treatment, which documented CD4 count, 
full blood count, liver-function tests, and medical 
problems. Providers of antiretroviral therapy had a 
minimum client preparation time for initiation of therapy 
of 6 weeks. Participants entered this pathway at the 
4-week point to not delay initiation of antiretroviral 
therapy. Providers independent of the trial team chose 
and monitored regimens of antiretroviral therapy (two 
nucleoside reverse transcriptase inhibitors and one 
non-nucleoside reverse transcriptase inhibitor).
Participants continued taking the trial drug until the 
end of the trial (minimum 12 weeks) or until their CD4 
count reached 200 cells per μL, at which point they were 
deemed to be no longer at risk of cryptococcal disease. 
Trial drug was also stopped if transaminases exceeded 
ﬁ ve times the ULN, if an adverse event deemed to be 
related to trial drug occurred, if women became pregnant, 
if participants wanted to leave the trial, or if they moved 
away from study area. Once trial drug was stopped, 
participants were reviewed at the clinic every 6 months.
Deaths and potential episodes of cryptococcal disease 
were retrospectively reviewed by an independent 
endpoint review committee. Those who died outside 
hospital had a verbal autopsy, and their most recently 
Figure 1: Trial proﬁ le
5337 assessed for eligibility
1519 enrolled
759 assigned to placebo
587 discontinued intervention
 380 reached CD4 >200
 93 died
 59 safety concerns
 32 pregnant
 19 lost to follow-up
 4 wanted to leave study
590 discontinued intervention 
 371 reached CD4 >200
 96 died
 59 safety concerns
 22 pregnant
 31 lost to follow-up
 11 wanted to leave study
760 assigned to ﬂuconazole
172 ended trial 170 ended trial
759 analysed by intention to treat 760 analysed by intention to treat
3818 not enrolled
 3299 CD4 >200
 69 abnormal LFT
 59 CrAg positive
 48 refractory candida
 6 pregnant of breastfeeding
 53 medically unﬁt
 68 refused or unable to consent
 131 did not attend for enrolment
 11 moved out of area
 74 other
Placebo (n=759) Fluconazole (n=760)
Sex
Male 251 (33%) 286 (38%)
Female 508 (67%) 474 (62%)
Age (years, mean [SD]) 35·8 (8·8) 35·9 (9·1)
Age group (years)
<25 47 (6%) 58 (8%)
25–34 323 (43%) 306 (40%)
35–44 270 (36%) 269 (35%)
>45 119 (16%) 127 (17%)
CD4 count (median (IQR)) 112 (48–157) 110 ( 45–160)
CD4 count (grouped)
150–199 231 (30%) 237 (31%)
100–149 185 (24%) 168 (22%)
50–99 150 (20%) 152 (20%)
1–49 193 (25%) 203 (27%)
WHO stage
1 20 (3%) 18 (2%)
2 164 (22%) 175 (23%)
3 524 (69%) 506 (67%)
4 51 (7%) 61 (8%)
Data are n (%) unless otherwise stated. Percentages might not total 100 because 
of rounding.
Table 1: Baseline characteristics
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stored serum was tested for CrAg. The  endpoint review 
committee had access to participants’ ﬁ les, hospital 
notes, verbal autopsy data, and retrospective CrAg results, 
but were masked to treatment group.
Endpoints
The two co-primary endpoints were time to ﬁ rst episode 
of invasive cryptococcal disease and all-cause mortality. 
All-cause mortality was redeﬁ ned as a primary endpoint 
(previously a secondary endpoint) in place of mortality 
from cryptococcal disease in 2006, when it became 
clear that both the number of cryptococcal events and 
the case-fatality rate was lower than anticipated (after 
enrolment of 796 participants). Secondary eﬃ  cacy 
endpoints were: time to ﬁ rst episode of oesophageal 
candidosis, time to ﬁ rst episode of oropharyngeal or 
vaginal candidosis, time to ﬁ rst hospital admission or 
death, incidence of candidosis (allowing for multiple 
episodes), and incidence of hospital admission 
(allowing for multiple admissions). The primary safety 
endpoint was cessation of trial drug because of high 
concentration of transaminases (>5×ULN) or other 
major adverse event.
Statistical Analysis
The original sample size of 590 participants was based 
on an annual incidence rate of invasive cryptococcal 
disease of 10·3% and had 80% power to detect a 75% 
reduction in the incidence of cryptococcal disease at the 
5% signiﬁ cance level. Because antiretroviral therapy 
became available in Uganda, the sample size was re-
estimated to account for the reduction in cryptococcal 
incidence in participants who started the therapy. 
Recruitment of 770 participants in each group (to 
contribute 530 person-years of obser vation) was estimated 
to give 80% power to detect a reduction of 75% in 
cryptococcal disease at the 5% level (22 cryptococcal 
events).
We analysed all endpoints by intention to treat including 
all enrolled participants. Participants were deemed to be at 
risk of an event until they had the event, stopped taking 
trial drug because of their CD4 count reaching 200 cells 
per μL, died, or the trial ended. Those who stopped the trial 
drug because of an adverse event or pregnancy were 
deemed at risk until end of trial. Participants lost to follow-
up or who withdrew were deemed at risk until the last time 
seen. We analysed the primary outcomes using survival 
analysis. We used Kaplan-Meier survival curves to show 
the time to event in the two treatment groups and a log-
rank test to see whether distributions diﬀ ered between 
groups. A further log-rank test stratiﬁ ed the exposure time 
by status of antiretroviral therapy. We ﬁ tted Cox regression 
models with terms for baseline concentrations of CD4 cells 
(categorised as <50, 50–99, 100–149, or 150–199 cells per μL 
for mortality, and as <50 or 50–199 cells per μL for 
cryptococcal events due to small numbers) and for status 
of antiretroviral therapy as a time-varying covariate. We did 
a formal test examining a potential interaction of 
Age (years) Sex Time to event 
(days)*
Time on ART 
(days)
CD4 count (cells 
per μL)†
Serum CrAg titre 
(at diagnosis)
Blood culture CSF CrAg CSF culture Died within 4 weeks
1‡ 32 M 71 ·· 14 1/512 C neoformans Positive C neoformans No
2 31 M 215 78 18 Negative C neoformans Negative Negative Yes
3 36 F 117 56 139 1/32§ Negative Negative Negative No
4 35 M 132 39 30 1/128 Negative Positive Negative No
5 38 M 105 7 124 1/1024 C neoformans Positive C neoformans No
6 46 M 101 3 31 1/1024 C neoformans Positive C neoformans No
7 33 F 117 ·· 14 1/128 C neoformans Negative Negative No
8 30 F 27 ·· 3 1/1024 C neoformans Positive C neoformans No
9 35 F 62 ·· 2 1/1024 NA NA C neoformans Yes
10 33 M 59 ·· 78 1/512 Negative Positive C neoformans No
11 58 F 85 13 66 1/16§ Negative Negative Negative No
12 52 M 66 ·· 27 1/512 C neoformans Positive C neoformans No
13 34 M 185 ·· 76 1/2048 C neoformans Positive C neoformans No
14 31 F 6 ·· 70 1/256 C neoformans Positive C neoformans No
15 39 M 101 38 7 1/128 Negative Positive Negative No
16 37 M 55 ·· 26 1/512 C neoformans Positive C neoformans No
17 32 M 48 ·· 8 1/512§ Negative NA NA Yes
18 38 F 41 ·· 8 1/512 C neoformans Positive C neoformans No
19 28 F 13 ·· 15 1/8 C neoformans Positive Negative No
ART=antiretroviral therapy. CrAg=cryptococcal antigen. CSF=cerebrospinal ﬂ uid. NA=not available. M=male. F=female. *Time from trial enrolment to cryptococcal event (second CrAg for those diagnosed on 
CrAg alone). †CD4 count at study enrolment. ‡On ﬂ uconazole. §Diagnosed on serum CrAg alone.
Table 2: Diagnosis of cryptococcal events
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antiretroviral therapy by treatment group for all-cause 
mortality; too few events occurred to do this analysis for 
the cryptococcal primary endpoint. We applied a Bonferroni 
correction to adjust for multiple signiﬁ cance testing and 
used a 2·5% signiﬁ cance level for the two primary 
endpoints. We used similar methods to analyse the 
secondary endpoints. To assess the incidence of any 
episode of candidosis or hospital admissions, we adapted 
survival analysis methods to allow for multiple events 
within participants, as described by Cleves.28
Role of the funding source
The sponsors of the study did not have a role in design, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Of 5337 participants screened, 759 were randomly as-
signed to placebo and 760 to ﬂ uconazole (ﬁ gure 1). The 
baseline characteristics of the two groups were well 
balanced (table 1). More women than men were enrolled, 
which is consistent with the usual pattern of HIV-care 
seeking in Uganda.29 Participants were at risk in the 
primary analysis for a median of 30 weeks (IQR 25–53) 
on placebo and 30 weeks (25–54) on ﬂ uconazole. The 
median total follow-up was 60 weeks (28–123) on placebo 
and 59 weeks (27–124) on ﬂ uconazole. About half of 
participants stopped trial drug because their CD4 count 
reached 200 cells per μL (ﬁ gure 1), a quarter stopped at 
the end of the trial; 54 (3·5%) stopped due to pregnancy; 
50 (3·3%) were lost to follow-up, and 15 (1·0%) withdrew 
consent. All other participants stopped because of a 
cryptococcal or safety endpoint (ﬁ gure 1). 1298 participants 
(85%) started antiretroviral therapy (641 given ﬂ uconazole 
and 657 given placebo) at a median time of 11 weeks 
(IQR 7–17) after enrolment, of whom 1063 (82%) received 
a regimen containing nevirapine. The median time to 
antiretroviral therapy was 82 days for the ﬂ uconazole 
group and 87 days for the placebo group.
18 participants given placebo and one given ﬂ uconazole 
developed cryptococcal disease (table 2). The risk of 
developing the disease was signiﬁ cantly higher in the 
placebo group than in the ﬂ uconazole group (log-rank 
χ²=15·3, p=0·0001) (table 3, ﬁ gure 2). The HR for 
development of cryptococcal disease on placebo compared 
with that on ﬂ uconazole was 18·7 (95% CI 2·5–140·7), 
adjusting for baseline CD4 count and whether or not the 
participant was on antiretroviral therapy. Fluconazole 
reduced cryptococcal events both before and after start of 
antiretroviral therapy (table 3). No cryptococcal events 
occurred in participants who stopped taking trial drug 
when their CD4 count reached 200 cells per μL. The 
overall rate of cryptococcal events was higher in the 
placebo group than in the ﬂ uconazole group (table 3). On 
average, 44·6 patients would require ﬂ uconazole 
prophylaxis to prevent one case of crypto coccal disease.
Overall Before antiretroviral therapy On antiretroviral therapy
Placebo Fluconazole Placebo Fluconazole Placebo Fluconazole
Events Rate 
(per 
100 
PYO)
Events Rate 
(per 
100 
PYO)
Unadjusted 
log-rank χ² 
(p value)
aHR* 
(95% CI) 
Hetero-
geneity 
log-rank χ² 
(p value)
Events Rate 
(per 
100 
PYO)
Events Rate 
(per 
100 
PYO)
aHR† 
(95% CI)
Events Rate 
(per 
100 
PYO)
Events Rate 
(per 
100 
PYO)
aHR† 
(95% CI)
Primary outcomes
Cryptococcal 
disease
18 2·8 1 0·15 15·3 
(p=0·0001)
18·7 
(2·5–140·7)
Non-
estimable
11 5·1 1 0·5 11·0 
(1·4–85·3)
7 1·6 0 0 ∞‡ 
(1·45–∞)
Deaths on trial drug 93 14·1 96 14·5 0·05 
(p=0·82)
0·96 
(0·72–1·27)
0·55 
(p=0·46)
·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Secondary outcomes
First episode of 
oesophageal 
candidiasis
55 8·7 6 0·91 40·8 
(p<0·001)
9·4 
(4·0–21·8)
5·44 
(p=0·02)
45 21·3 2 0·96 22·2 
(5·4–91·7)
10 2·4 4 0·89 2·9 
(0·91–9·3)
First episode of 
oropharyngeal or 
vaginal candidosis
159 29·5 24 3·7 116·6 
(p<0·0001)
7·4 
(4·8–11·4)
5·40 
(p=0·02)
119 61·4 11 5·3 11·4 
(6·1–21·1)
40 11·6 13 3 4·0 
(2·1–7·4)
Hospital admission 
or death
235 44·3 229 42·5 0·2 
(p=0·67)
1·05 
(0·87–1·26)
1·04 
(p=0·31)
·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Incidence of 
hospital admissions
284 43·7 278 42·6 0·1 
(p=0·73)
1·0 
(0·9–1·2)
0·34 
(p=0·56)
·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Incidence of all 
candidosis
272 41·2 29 4·4 198·6 
(p<0·0001)
9·6 
(6·5–14·1)
7·10 
(p=0·008)
187 85·7 12 5·7 14·8 
(8·2–26·5)
85 19 17 3·8 5·3 
(3·1–8·9)
PYO=person-years of observation. aHR=adjusted HR. *HR adjusted for baseline CD4 group and for before or after starting antiretroviral therapy as time varying covariate. †HR adjusted for baseline CD4 group. 
‡Exact CI for rate ratio was used since HR could not be estimated because no cryptococcal events occurred on the ﬂ uconazole group after starting antiretroviral therapy. 
Table 3: Eﬃ  cacy outcomes
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Of the 19 developing cryptococcal disease, 13 (68%) had 
a CD4 count of less than 50 cells per μL at the time of 
diagnosis, four (21%) had a CD4 count of 50–99 cells 
per μL, and the remaining two (11%) had CD4 counts of 
124 cells per μL and 139 cells per μL (table 1). Cryptococcal 
infection occurred predominantly in patients with WHO 
stage 3 (12 [63%]) or 4 (four [21%]) at baseline. The 
number needed to treat was 22·8 for those with a baseline 
CD4 count of less than 100 cells per μL (two events 
missed) and 44·1 for baseline WHO stage 3 and 4 together. 
Positive cryptococcal cultures, including the one in the 
ﬂ uconazole group, were all sensitive to ﬂ uconazole.
Fluconazole had no eﬀ ect on survival (table 3). The HR 
for death in the placebo group versus that in ﬂ uconazole 
group was close to 1, adjusting for baseline CD4 count 
and ART status as a time dependent covariate (table 3). 
The endpoint review committee judged cryptococcal 
disease to be the deﬁ nite cause of death in seven 
participants and a possible cause of death in one; all were 
in the placebo group. Nine deaths (ﬁ ve in the placebo 
group, four in the ﬂ uconazole group) occurred after 
participants had stopped taking the trial drug. Including 
these deaths in the survival analysis changed the adjusted 
HR from 0·96 to 0·97.
Fluconazole signiﬁ cantly reduced the incidence for the 
ﬁ rst episode of all types of candidosis (p<0·0001; table 3). 
The eﬀ ect of ﬂ uconazole was greater before than after 
antiretroviral therapy (table 3). Overall, 63 participants 
developed 74 episodes of oesophageal candidiasis: 
66 episodes in 55 participants given placebo and eight 
episodes in eight participants given ﬂ uconazole. The 
incidence for ﬁ rst occurrence of oesophageal candidosis 
in the placebo group dropped from 21·3 per 100 person-
years of observation before antiretroviral therapy to 
2·39 per 100 person-years of observation after the therapy, 
but remained constant in the ﬂ uconazole group (table 3). 
Fluconazole also reduced oral and vaginal candidosis 
(p<0·0001) with a stronger eﬀ ect before therapy (table 3) 
than after therapy. The eﬀ ect of ﬂ uconazole on oral 
candidosis alone was also greater before than after 
antiretroviral therapy, although still signiﬁ cant after 
initiation of the treatment (data not shown). The eﬀ ect of 
ﬂ uconazole on vaginal candidosis alone was similar 
before and after therapy (data not shown). The incidence 
of hospital admission or death did not diﬀ er between the 
two groups (table 3).
59 participants on placebo and 59 on ﬂ uconazole stopped 
trial drug because of safety concerns (table 4). 115 partici-
pants had transaminases more than ﬁ ve-times the ULN 
(57 in the placebo group, 58 in the ﬂ uconazole group) 
and three had Stevens-Johnson syndrome (two placebo, 
one ﬂ uconazole). The use of nevirapine as antiretroviral 
therapy did not increase the risk of hepatotoxic eﬀ ects. In 
those given nevirapine, 27 (5%) of 522 in the ﬂ uconazole 
group and 34 (6%) of 541 in the placebo group stopped 
trial drug because of elevated transaminases. 54 women 
became pregnant; they were reviewed by an independent 
doctor during pregnancy and infants were reviewed by a 
paediatrician. There was no evidence of excess 
miscarriage (seven of 32 in the placebo group, six of 22 in 
the ﬂ uconazole group, p=0·65), stillbirth (none of 13 live 
births in the placebo group vs one of eight in the 
Placebo 
(n=759)
Fluconazole 
(n=760)
Unadjusted log 
rank (p value)
aHR* (95% CI)
Event Rate† Events Rate†
Withdrawal of trial drug
Due to an adverse event 59 9·9 59 9·6 0·00 (p=0·99) 1·04 (0·72–1·49)
Due to LFT>5×ULN 57 9·6 58 9·5 0·01 (p=0·93) 1·02 (0·70–1·47)
Due to other adverse event 2 0·33 1 0·16 0·32 (p=0·57) 1·99 (0·18–22·2)
Pregnancy 32 7·8 22 5·4 1·83 (p=0·18) 1·44 (0·84–2·49)
Serious  adverse events
Life threatening ‡ 53 (49) 8·29 49 (42) 7·62 0·16 (p=0·69) 1·02 (0·69–1·51)
Anaemia (grade 4) 49 10·0 62 12·8 1·38 (p=0·24) 0·79 (0·54–1·15)
Events resulting  in disability 9 1·38 5 0·76 1·17 (p=0·28) 1·88 (0·63–5·65)
Reported side-eﬀ ects
Nausea 38 6·11 35 5·57 0·11 (p=0·74) 1·09 (0·69–1·72)
Headache 9 1·39 10 1·53 0·06 (p=0·81) 0·89 (0·36–2·19)
Abdominal pain 25 3·91 22 3·42 0·21 (p=0·65) 1·13 (0·64–2·01)
Rash 27 4·27 17 2·64 2·36 (p=0·12) 1·59 (0·86–2·91)
Other 49 8·01 46 7·41 0·10 (p=0·75) 1·07 (0·72–1·61)
Participants reporting at 
least one side-eﬀ ect
136 25·35 123 22·12 0·83 (p=0·36) 1·12 (0·88–1·43)
Other
Loss to follow-up 19 3·30 31 5·15 2·43 (p=0·12) 0·60 (0·34–1·07)
Withdrawal 4 0·69 11 1·83 3·15 (p=0·076) 0·36 (0·12–1·14)
aHR=adjusted HR. LFT=liver-function test. ULN=upper limit of normal. *Adjusted for baseline CD4 group and for 
before or after start of antiretroviral therapy as time varying covariate. †Rates are per 100 person-years of observation. 
‡Numbers of patients are indicated in brackets.
Table 4: Safety, toxicity, and loss to follow–up
Figure 2: Incidence of cryptococcal disease by treatment group
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ﬂ uconazole group, Fishers exact p=0·38), or ﬂ uconazole-
related abnormalities in live born babies. Severe (grade 4) 
anaemia did not diﬀ er between groups. Mild side-eﬀ ects 
attributed by the study physicians to the trial drug 
(including headache, nausea, and abdominal pain) were 
experienced by 259 participants (136 given placebo and 
123 given ﬂ uconazole).
Loss to follow-up and withdrawal events were more 
frequent in the ﬂ uconazole group than in the placebo 
group (table 4). Withdrawal occurred at a median of 
83 days (IQR 26–174) and loss to follow-up at a median of 
138 days (IQR 84–195); the timing of antiretroviral therapy 
or the proportion of participants who started the therapy 
did not diﬀ er between groups. 26 of 50 partici pants lost to 
follow-up were subsequently located and known to be 
alive: a chance imbalance in movement from the trial area 
(ten of 31 in the ﬂ uconazole group, three of 19 in the 
placebo group) was a major contributor to the diﬀ erence.
Discussion
This trial showed ﬂ uconazole to be highly eﬀ ective and 
safe in the prevention of invasive cryptococcal disease 
with a protective eﬀ ect that occurred both before the 
start and in the ﬁ rst months of antiretroviral therapy. 
The overall degree of protection was much greater than 
that seen in the only other large randomised trial of azole 
prophylaxis (panel),9 but, despite this result, ﬂ uconazole 
prophylaxis had no eﬀ ect on survival. The incidence of 
cryptococcal disease and number of cryptococcal events 
was lower than that predicted when the trial was 
designed; the rapid roll out of antiretroviral therapy in 
Uganda was unexpected. Patients were enrolled with 
CD4 counts of less than 200 cells per μL in the expectation 
that CD4 counts would drop during the trial. However, 
most patients started antiretroviral therapy within 
3 months of enrolment, which reduced substantially the 
time at risk of crypto coccal disease; 774 (51%) of 
1519 patients never had a CD4 count less than 100 cells 
per μL. The trial steering group considered this issue 
during the trial but felt that reduction of the CD4 entry 
criteria in the middle of the trial was not appropriate. 
Additionally, randomisation of patients with a positive 
CrAg at baseline was deemed unethical. The study, 
therefore, excluded participants with incipient 
cryptococcal disease or those at highest risk of developing 
the disease.
The low incidence of cryptococcal disease and low case 
fatality rate (seven [37%] of 19) due to intensive surveil-
lance and rapid initiation of treatment meant that, 
although a strong eﬀ ect was recorded on cryptococcal-
speciﬁ c mortality (none vs seven deaths), no eﬀ ect was 
noted on all-cause mortality. In fact, only results from 
one study in Thailand20 (of 90 patients) have shown 
a survival advantage in HIV-infected patients from 
azole prophylaxis (HR 4·3 [95% CI 0·9–19·8], p=0·065); 
although there was a trend towards a reduction in 
cryptococcal disease with ﬂ uconazole, only two of the 
nine deaths in the placebo group were attributed to 
cryptococcal disease.20
Fluconazole was safe in routine use: the incidence of 
hepatic enzyme elevation of grade 3 or 4 was similar in 
the two groups. We found no evidence of hepatoxic 
eﬀ ects when ﬂ uconazole was given with nevirapine, in 
keeping with other studies.32 The safety of ﬂ uconazole at 
this prophylactic dose means that it could be used in 
clinics without laboratory support.
The trial population was representative of a rural sub-
Saharan African setting and the ﬁ ndings were robust 
with similar baseline ﬁ ndings and antiretroviral 
treatment in each group. Higher rates of cryptococcal 
disease than those seen in this trial have been described 
previously in Africa and case-fatality rates reach 60% 
even when antiretroviral therapy is available.1–3 Both the 
proportion of patients accessing the therapy and the 
speed of its access were unusual in our study. In routine 
practice in sub-Saharan Africa, where access to 
antiretroviral therapy is often restricted, or in other 
continents with limited access, the beneﬁ ts of ﬂ uconazole 
prophylaxis might be even greater. Cryptococcal events 
occurred no later than 3 months after initiation of anti-
retroviral therapy suggesting the need for a restricted 
duration of prophylaxis once prophylaxis is started. The 
reduction of oesophageal, oral, and vaginal candidosis is 
an additional beneﬁ t.
The results of this trial have substantial policy impli-
cations. Less than half of people needing antiretroviral 
therapy in sub-Saharan Africa currently access the 
treatment, and low CD4 counts at presentation are 
common.33,34 Initiation of treatment is often delayed by 
several weeks because of stock-outs.35,36 Up to 20% of 
early mortality on antiretroviral therapy is due to crypto-
coccal disease in sub-Saharan Africa.1 In this context, 
Panel: Research in context
Systematic review
We searched PubMed using combinations of the terms “cryptococcus”, “cryptococcal 
disease”, “cryptococcal meningitis”, “azole”, and “prophylaxis”.  A Cochrane Review19 has 
examined azole primary prophylaxis against cryptococcal disease. The ﬁ ve studies 
included 1500 patients in total and two small studies (219 patients) from Thailand, but 
none from Africa. Azole prophylaxis reduced the incidence of cryptococcal disease 
(relative risk 0·21) but did not aﬀ ect mortality.
Interpretation
This study is the ﬁ rst to investigate the role of primary prophylaxis in Africa where the 
burden of cryptococcal disease is greatest, and is also the ﬁ rst to include a large 
proportion of patients commencing antiretroviral therapy. Unlike previous studies, only 
individuals who were CrAg negative were included in the trial. Fluconazole was highly 
eﬀ ective in reducing the risk of cryptococcal disease both before and after initiation of 
antiretroviral therapy. Recent data30,31 suggest that there is beneﬁ t in CrAg screening and 
treatment of CrAg positivity before antiretroviral therapy. Results from this study show 
that ﬂ uconazole primary prophylaxis is a complementary strategy that can prevent the 
development of cryptococcal disease in those waiting for antiretroviral therapy or in those 
with low CD4 counts in the early stages of the treatment.
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ﬂ uconazole prophylaxis buys time for the patient to 
start treatment and protects against cryptococcal disease 
until immune reconstitution occurs. Fluconazole 
prophylaxis is therefore of enormous potential beneﬁ t 
for individuals who are unable to access or who are 
waiting for anti retroviral therapy, or for those negative 
for CrAg with low CD4 counts (<100 cells per μL) in the 
early stages of therapy.
Results from studies30,31 have shown that a positive 
screening for CrAg predicts a high risk of cryptococcal 
disease and mortality at the start of antiretroviral 
therapy. In one study,31 no-one with a negative CrAg 
measured shortly before initiation of therapy developed 
cryptococcal disease; CrAg screening at initiation of 
therapy may be cost eﬀ ective.37 Primary prophylaxis 
with ﬂ uconazole is a complementary strategy. CrAg 
positivity identiﬁ es those at highest risk, but we have 
shown that patients negative for CrAg might develop 
cryptococcal disease when there is a delay between 
CrAg screening and initiation of antiretroviral therapy. 
Modelling of data from Cambodia38 suggested that 
screening was more cost eﬀ ective than prophylaxis if 
the CD4 count was higher than 50 cells per μL. We 
believe that the relative beneﬁ t of screening or 
prophylaxis for those with CD4 counts of more than 
100 cells per μL predominantly depends on the delay 
before initiation of antiretroviral therapy.
Overall, our results provide substantial evidence to 
support present WHO recommendations that “in areas 
where cryptococcal disease is common, antifungal 
prophylaxis with azoles should be considered for severely 
immunocompromised people with HIV (WHO clinical 
stage 4 or CD4 <100 cells per μL), whether on antiretroviral 
therapy or not.”39 However, our data suggest that WHO 
clinical stage 3 should be included. Fluconazole is a safe, 
well tolerated intervention that could be given in the 
community, improving quality of life by reduction of 
candida infections and prevention of cryptococcal disease 
in patients waiting to access or in the early phase of 
antiretroviral therapy.
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